Portal de Periódicos da CAPES

Raltitrexed–eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer

2006; Springer Nature; Volume: 94; Issue: 6 Linguagem: Inglês

10.1038/sj.bjc.6603026

1532-1827

Michele Reni, Lara Maria Pasetto, Giuseppe Aprile, Stefano Cordio, E. Bonetto, Stefania Dell’Oro, P. Passoni, Lorenzo Piemonti, Clara Fugazza, Gabriele Luppi, Carlo Milandri, Roberto Nicoletti, Alessandro Zerbi, Gianpaolo Balzano, Valerio Di Carlo, Alba A. Brandes,

Neuroendocrine Tumor Research Advances

Limited information on salvage treatment in patients affected by pancreatic cancer is available. At failure, about half of the patients present good performance status (PS) and are candidate for further treatment. Patients >18 years, PS ⩾50, with metastatic pancreatic adenocarcinoma previously treated with gemcitabine-containing chemotherapy, and progression-free survival (PFS) 2 toxicity was: neutropenia in five patients (12%), thrombocytopenia, liver and vomiting in three (7%), fatigue in two (5%). In total, 10 patients (24%) yielded a partial response, 11 a stable disease. Progression-free survival at 6 months was 14.6%. Median survival was 5.2 months. Survival was significantly longer in patients with previous PFS >6 months and in patients without pancreatic localisation. A clinically relevant improvement of quality of life was observed in numerous domains. Raltitrexed–oxaliplatin regimen may constitute a treatment opportunity in gemcitabine-resistant metastatic pancreatic cancer. Previous PFS interval may allow the identification of patients who are more likely to benefit from salvage treatment.